BENDAMUSTINE clinical trials

Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)

This study compares a new cell therapy (Tisagenlecleucel) with standard treatments for adults with an aggressive type of lymphoma that has come back or not responded to previous therapy. Researchers want to see which treatment is better at stopping the cancer from growing.

A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma

This study looks at a new type of cell therapy, called MB-CART2019.1, for people with a specific type of lymphoma that has come back or hasn't responded to other treatments. It checks how safe and effective it is.

A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma

This study is testing a new cell therapy called durcabtagene autoleucel for adults with multiple myeloma that has come back or isn't responding to other treatments. It aims to see how well the treatment shrinks the cancer and improves patients' health.

Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)

This study is looking at a new treatment combination — rituximab, bendamustine, cytarabine, and venetoclax (V-RBAC) — for older patients with a specific type of blood cancer called mantle cell lymphoma. It aims to see how well this new treatment stops the cancer from growing for at least two years.

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

This study looks at a new drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares BGB-16673 to existing treatments in patients whose cancer has come back after trying two other types of drugs.

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

This study is testing a new drug, odronextamab, for adults with follicular lymphoma that hasn't been treated before. It aims to find out if the drug is safe and how well it works compared to current standard treatments.

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

This study is testing a new medicine called FT819 for serious autoimmune diseases like lupus and vasculitis. It's looking at how safe it is and how well it works to reduce disease activity, especially in those who haven't responded to other treatments.

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

This study is looking at a new medicine called acalabrutinib for chronic lymphocytic leukaemia (CLL). It compares acalabrutinib to usual treatments to see which works best for people whose CLL has come back or hasn't responded to previous treatment.

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

This study looks at a new drug, golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or not responded to previous treatments. It compares this new combination to standard treatments chosen by doctors.

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

This study is looking at a new medicine called duvelisib for people in the UK with a specific type of T-cell lymphoma that has come back or not responded to previous treatments. It compares duvelisib to standard treatments like gemcitabine or bendamustine to see if it helps patients live longer without their cancer getting worse.

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

This study compares a new medicine, pirtobrutinib, with standard treatment (bendamustine and rituximab) for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see which is safer and works better.

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

This study looks at new treatments for Mantle Cell Lymphoma in adults who can't have a stem cell transplant. It compares two drug combinations to see which works better and is safer.

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

This study looks at a new drug, Pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares Pirtobrutinib to standard treatments to see if it works better for those who have already tried other therapies.

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

This study compares a new drug, zanubrutinib, with standard treatments (bendamustine and rituximab) for adults with previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL). Researchers want to see which treatment works best to stop the cancer from getting worse.

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

This study is looking at a new treatment called axicabtagene ciloleucel for follicular lymphoma that has come back or hasn't responded to other treatments. It compares this new treatment to standard care to see how well it works.

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.

A Phase 2 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

The REFRACT trial explores new treatments for follicular lymphoma that has come back or not responded to previous therapy. It compares new drugs with standard care to see if they offer better results for patients.